Copenhagen, 2012-01-18 11:01 CET (GLOBE NEWSWIRE) --
Copenhagen, Denmark - January 18, 2012 - Today Topotarget A/S (NASDAQ OMX: TOPO.CO) announced that clinical data on belinostat will be presented at The 2012 Gastrointestinal Cancers Symposium, January 19-21, 2012.
Shown below is the abstract that is now available for viewing on the ASCO.org website (www.asco.org).
Efficacy of belinostat in advanced hepatocellular carcinoma (HCC): Phase I and II multicentered study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG).
Abstract No.: 259
Session: General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Background:
Belinostat is a novel histone deactylase inhibitor
which demonstrates preclinical activity in HCC. We report
the results of a phase I/II study in belinostat in patients
(pts) with unresectable HCC.
Methods:
Major eligibility criteria included histologically
confirmed HCC not amenable to curative treatment; PS